HLA-A and rectum adenocarcinoma: Next, we analyzed the cell line RCM1, a rectal adenocarcinoma cell line with KRAS-G12V mutation without HLA-A*11:01, to determine whether any oncogenic KRAS-carrying neoantigens would be identified from different HLA allotypes.